» Articles » PMID: 26151174

Impact of Prolonged Exacerbation Recovery in Chronic Obstructive Pulmonary Disease

Overview
Specialty Critical Care
Date 2015 Jul 8
PMID 26151174
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Rationale: Exacerbations are important and heterogeneous events in the natural history of chronic obstructive pulmonary disease (COPD).

Objectives: To examine the consequences of prolonged exacerbation recovery in patients with COPD.

Methods: A cohort of 384 patients with COPD (FEV1 % predicted 45.8 [SD, 16.6] and a median exacerbation rate of 2.13 per year [interquartile range, 1.0-3.2]) were followed for 1,039 days (interquartile range, 660-1,814) between October 1995 and January 2013. Patients recorded daily worsening of respiratory symptoms and peak expiratory flow (PEF), and when stable underwent spirometry every 3 months, and completed the St. George's Respiratory Questionnaire annually. Exacerbations were diagnosed as 2 consecutive days with one major symptom plus another respiratory symptom. Exacerbation duration was defined as the time from onset to the day preceding 2 consecutive symptom-free days and recovery in PEF as return to preexacerbation levels.

Measurements And Main Results: A total of 351 patients had one or more exacerbations. Patients with a longer symptom duration (mean, 14.5 d) had a worse St. George's Respiratory Questionnaire total score (0.2 units per 1 day; P = 0.040). A longer symptomatic duration was associated with a shorter interval between exacerbation recovery and onset of the next exacerbation (hazard ratio, 1.004; P = 0.013). For 257 (7.3%) exacerbations, PEF did not recover within 99 days. These exacerbations were associated with symptoms of a viral infection (cold and sore throat). Patients with these nonrecovered exacerbations showed a 10.8 ml/yr (P < 0.001) faster decline in FEV1.

Conclusions: Prolonged exacerbation symptomatic duration is associated with poorer health status and a greater risk of a new event. Exacerbations where lung function does not recover are associated with symptoms of viral infections and accelerated decline in FEV1.

Citing Articles

The use of the Prospector calculator reduces antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.

Paprocki M, Zwirowski S, Kuziemski K Sci Rep. 2025; 15(1):1969.

PMID: 39809919 PMC: 11732986. DOI: 10.1038/s41598-025-85388-2.


Exacerbations of bronchiectasis.

De Angelis A, Johnson E, Sutharsan S, Aliberti S Eur Respir Rev. 2024; 33(173).

PMID: 39048130 PMC: 11267293. DOI: 10.1183/16000617.0085-2024.


Increasing exercise capacity and physical activity in the COPD patient.

Kaur A, Bourbeau J, Brighton L, Celli B, Crouch R, Demeyer H Breathe (Sheff). 2024; 20(2):230347.

PMID: 38873235 PMC: 11167654. DOI: 10.1183/20734735.0347-2023.


Accelerated Lung Function Decline and Mucus-Microbe Evolution in Chronic Obstructive Pulmonary Disease.

Meldrum O, Donaldson G, Narayana J, Ivan F, Jaggi T, Mac Aogain M Am J Respir Crit Care Med. 2024; 210(3):298-310.

PMID: 38315959 PMC: 11348959. DOI: 10.1164/rccm.202306-1060OC.


Phenotypes, Etiotypes, and Endotypes of Exacerbations of Chronic Obstructive Pulmonary Disease.

Bhatt S, Agusti A, Bafadhel M, Christenson S, Bon J, Donaldson G Am J Respir Crit Care Med. 2023; 208(10):1026-1041.

PMID: 37560988 PMC: 10867924. DOI: 10.1164/rccm.202209-1748SO.


References
1.
Niewoehner D, Erbland M, DEUPREE R, Collins D, Gross N, Light R . Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999; 340(25):1941-7. DOI: 10.1056/NEJM199906243402502. View

2.
Bhowmik A, Seemungal T, Sapsford R, Wedzicha J . Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000; 55(2):114-20. PMC: 1745686. DOI: 10.1136/thorax.55.2.114. View

3.
Seemungal T, Donaldson G, Bhowmik A, Jeffries D, Wedzicha J . Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000; 161(5):1608-13. DOI: 10.1164/ajrccm.161.5.9908022. View

4.
Seemungal T, Bhowmik A, Jeffries D, Wedzicha J . Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J. 2000; 16(4):677-83. PMC: 7163563. DOI: 10.1034/j.1399-3003.2000.16d19.x. View

5.
Kanner R, Anthonisen N, Connett J . Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med. 2001; 164(3):358-64. DOI: 10.1164/ajrccm.164.3.2010017. View